Filing Flows › Vanda Pharmaceuticals (VNDA) › Q3 2026 › vs Q2 2026
Vanda Pharmaceuticals (VNDA) Q3 2026 vs Q2 2026 (quarter over quarter)
Vanda Pharmaceuticals's revenue rose $19.3M (+38%) from $50.5M in Q2 2026 to $69.8M in Q3 2026. The biggest changes: HETLIOZ® net product sales +$16.1M (+289%); Fanapt® +$2.8M (+8%); NEREUSTM +$583K (+57%).
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Fanapt® | $38.8M | $36.0M | $2.8M | +8% |
| HETLIOZ® net product sales | $21.7M | $5.6M | $16.1M | +289% |
| PONVORY® net product sales | $7.7M | $7.9M | −$186K | -2% |
| NEREUSTM | $1.6M | $1.0M | $583K | +57% |
| Revenue | $69.8M | $50.5M | $19.3M | +38% |
| Other income, net | $1.1M | $1.4M | −$292K | -20% |
| Net loss | $22.6M | $62.5M | −$40.0M | -64% |
| Costs & expenses | $93.5M | $114M | −$21.0M | -18% |
| Operating costs | $93.3M | $114M | −$21.0M | -18% |
| Income tax | $174K | $129K | $45K | +35% |
| Cost of revenue | $4.2M | $3.6M | $592K | +17% |
| Research & development | $27.6M | $37.0M | −$9.3M | -25% |
| SG&A | $59.6M | $71.8M | −$12.3M | -17% |
| Other operating costs | $2.0M | $2.0M | $0 | 0% |
| Operating cash sources | $33.0M | $35.4M | −$2.4M | -7% |
| Depreciation & amortization | $2.2M | $2.3M | −$24K | -1% |
| Share-based compensation | $2.3M | $2.1M | $232K | +11% |
| Cash used in operations | $28.4M | $31.1M | −$2.6M | -8% |
| Net loss absorbed | $22.6M | $62.5M | −$40.0M | -64% |
| Working capital & other | $10.4M | −$27.1M | $37.5M | — |
Questions
How much did Vanda Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Vanda Pharmaceuticals's revenue rose $19.3M (+38%) from $50.5M in Q2 2026 to $69.8M in Q3 2026.
What drove Vanda Pharmaceuticals's revenue change in Q3 2026?
HETLIOZ® net product sales +$16.1M (+289%); Fanapt® +$2.8M (+8%); NEREUSTM +$583K (+57%).